Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $23.71

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus recommendation of "Buy" by the nine analysts that are currently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $23.71.

ZVRA has been the topic of a number of research reports. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Cantor Fitzgerald increased their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Finally, HC Wainwright initiated coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target on the stock.

Zevra Therapeutics Stock Down 0.4%

NASDAQ ZVRA traded down $0.05 on Tuesday, hitting $12.62. 567,799 shares of the stock traded hands, compared to its average volume of 733,683. The stock has a 50-day moving average of $9.45 and a 200 day moving average of $8.32. Zevra Therapeutics has a twelve month low of $5.45 and a twelve month high of $13.16. The company has a market capitalization of $689.79 million, a P/E ratio of -6.62 and a beta of 1.97. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The firm had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. As a group, analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. BNP Paribas Financial Markets bought a new position in Zevra Therapeutics in the 4th quarter worth approximately $53,000. GAMMA Investing LLC boosted its stake in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after purchasing an additional 8,020 shares in the last quarter. Strs Ohio bought a new position in Zevra Therapeutics during the 1st quarter valued at $125,000. Squarepoint Ops LLC boosted its stake in Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after purchasing an additional 4,384 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Zevra Therapeutics during the 4th quarter valued at $145,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.